CD134 Recombinant Antibody, Cy5.5 Conjugated
Applications
Reactivity
| Overview | |
| Catalog # | bsm-60298r-Cy5.5 |
| Product Name | CD134 Recombinant Antibody, Cy5.5 Conjugated |
| Applications |
WB
FCM
IF(IHC-P)
IF(ICC)
|
| Reactivity | Human |
| Specifications | |
| Conjugation | Cy5.5 |
| Host | Rabbit |
| Source | KLH conjugated synthetic peptide derived from human CD134 |
| Clonality | Recombinant |
| Isotype | IgG |
| Concentration | Lot dependent |
| Purification | Purified by Protein A. |
| Storage Buffer | Aqueous buffered solution containing 0.01M TBS (pH 7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol. |
| Storage Condition | Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles. |
| Target | |
| Gene ID | 7293 |
| Swiss Prot | P43489 |
| Subcellular location | Cell membrane |
| Synonyms | CD134 / OX40L receptor; Tumor necrosis factor receptor superfamily member 4; TNFRSF4; ACT 35; ACT35; ACT35 antigen; CD 134; CD134 antigen; Lymphoid activation antigene ACT35; OX 40; OX40; OX40 antigen; OX40 cell surface antigen; OX40 homologue; OX40L receptor; TAX transcriptionally activated glycoprotein 1 receptor; TNFRSF 4; TNR4_HUMAN. |
| Background | The protein encoded by this gene is a member of the TNF-receptor superfamily. This receptor has been shown to activate NF-kappaB through its interaction with adaptor proteins TRAF2 and TRAF5. Knockout studies in mice suggested that this receptor promotes the expression of apoptosis inhibitors BCL2 and BCL2lL1/BCL2-XL, and thus suppresses apoptosis. The knockout studies also suggested the roles of this receptor in CD4+ T cell response, as well as in T cell-dependent B cell proliferation and differentiation. [provided by RefSeq, Jul 2008]. |
| Application Dilution | |
| WB | 1:500-2000 |
| FCM | FCM1:50-100 |
| IF(IHC-P) | IFIHC-P1:50-200 |
| IF(ICC) | IFICC1:50-200 |